Article citationsMore>>
Tsujimae, M., Yamashita, H., Hashimura, H., Kano, C., Shimoyama, K., Kanamori, A., Matsumoto, K., Koizumi, A., Momose, K., Eguchi, T., Fukuchi, T., Fujita, M. and Okada, A. (2016) A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. Digestion, 94, 240-246.
https://doi.org/10.1159/000454762
has been cited by the following article:
-
TITLE:
Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for Helicobacter pylori
AUTHORS:
Mika Miura, Masahiko Ohtaka, Mitsuhiko Hanawa, Naoki Shimura, Yoshioki Yoda, Sho Suzuki
KEYWORDS:
Vonoprazan, Eradication, Helicobacter pylori, Propensity Score Matching, Gastric Mucosal Atrophy
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.7 No.9,
September
28,
2017
ABSTRACT: Aim: To investigate the factors related to the effect of eradication therapy with vonoprazan for Helicobacter pylori (H. pylori). Methods: We retrospectively reviewed medical records of H. pylori-positive patients who received first-line (40 mg vonoprazan/60 mg lansoprazole or 20 mg rabeprazole, 1500 mg amoxicillin, 400 mg clarithromycin, all 2/day for 7 days) (n = 4118). H. pylori eradication was assessed by the 13C-urea breath test with success defined as a result of H. pylori eradication therapy using vonoprazan was more effective than standard triple therapy with proton pump inhibitor. Gastric mucosal atrophy was associated with treatment success.
Related Articles:
-
Valerii Ermakov, Volodymyr Kolomoets, Leonid Panasyuk, Baja Orasgulyev
-
Sayeedeh Abdollahi, Mohammad Reza Salehi Rad
-
Tyler Downing, Amy Mangla, Michael Banta, Suguru Nakamura
-
Dodji Magloire Inès Yevi, Josué Dejennin Georges Avakoudjo, Dètondji Fred Jean-Martin Hodonou, Yves Nsounfou Ngapna, Jean Sossa, Gilles Natchagandé, Fouad Kolawolé Yde Soumanou, Michel Michaël Agounkpé
-
Rakesh Kumar Ameta, Man Singh, B. S. Kitawat